Click Therapeutics
launched Rejoyn in April 2024, the first-and-only prescription digital therapeutic cleared by the FDA for the adjunctive treatment of major depressive disorder symptoms, and expanded it to Great Britain in June 2025.
- Country
- United States
FDA cleared
Depression treatment
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Digital therapeutics | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.